Mark Ayers
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)Indiana University School of MedicineIndiana University – Purdue University Indianapolis(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade(2017)3,762 cited
- → Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy(2018)2,281 cited
- → Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes(2015)2,208 cited
- → Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy(2005)1,881 cited
- → T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028(2018)979 cited
- → The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy(2003)608 cited